FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171665032> ?p ?o ?g. }

• W2171665032 abstract "Bronchial carcinoids are pulmonary neuroendocrine cell-derived tumors comprising typical (TC) and atypical (AC) malignant phenotypes. The 5-year survival rate in metastatic carcinoid, despite multiple current therapies, is 14-25%. Hence, we are testing novel therapies that can affect the proliferation and survival of bronchial carcinoids.In vitro studies were used for the dose-response (AlamarBlue) effects of acetazolamide (AZ) and sulforaphane (SFN) on clonogenicity, serotonin-induced growth effect and serotonin content (LC-MS) on H-727 (TC) and H-720 (AC) bronchial carcinoid cell lines and their derived NOD/SCID mice subcutaneous xenografts. Tumor ultra structure was studied by electron microscopy. Invasive fraction of the tumors was determined by matrigel invasion assay. Immunohistochemistry was conducted to study the effect of treatment(s) on proliferation (Ki67, phospho histone-H3) and neuroendocrine phenotype (chromogranin-A, tryptophan hydroxylase).Both compounds significantly reduced cell viability and colony formation in a dose-dependent manner (0-80 μM, 48 hours and 7 days) in H-727 and H-720 cell lines. Treatment of H-727 and H-720 subcutaneous xenografts in NOD/SCID mice with the combination of AZ + SFN for two weeks demonstrated highly significant growth inhibition and reduction of 5-HT content and reduced the invasive capacity of H-727 tumor cells. In terms of the tumor ultra structure, a marked reduction in secretory vesicles correlated with the decrease in 5-HT content.The combination of AZ and SFN was more effective than either single agent. Since the effective doses are well within clinical range and bioavailability, our results suggest a potential new therapeutic strategy for the treatment of bronchial carcinoids." @default.
• W2171665032 created "2016-06-24" @default.
• W2171665032 creator A5005931876 @default.
• W2171665032 creator A5026699953 @default.
• W2171665032 creator A5027854700 @default.
• W2171665032 creator A5030295153 @default.
• W2171665032 creator A5040566066 @default.
• W2171665032 creator A5049914982 @default.
• W2171665032 creator A5072764332 @default.
• W2171665032 date "2013-08-08" @default.
• W2171665032 modified "2023-10-18" @default.
• W2171665032 title "Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines" @default.
• W2171665032 cites W1480219105 @default.
• W2171665032 cites W1522776071 @default.
• W2171665032 cites W1598950494 @default.
• W2171665032 cites W1964151908 @default.
• W2171665032 cites W1964403908 @default.
• W2171665032 cites W1977914298 @default.
• W2171665032 cites W1985698425 @default.
• W2171665032 cites W1990923495 @default.
• W2171665032 cites W1995414327 @default.
• W2171665032 cites W1997117033 @default.
• W2171665032 cites W2014206688 @default.
• W2171665032 cites W2014687097 @default.
• W2171665032 cites W2027601285 @default.
• W2171665032 cites W2033035143 @default.
• W2171665032 cites W2034279633 @default.
• W2171665032 cites W2040691880 @default.
• W2171665032 cites W2047178318 @default.
• W2171665032 cites W2051349300 @default.
• W2171665032 cites W2054884455 @default.
• W2171665032 cites W2056959168 @default.
• W2171665032 cites W2057437339 @default.
• W2171665032 cites W2062011075 @default.
• W2171665032 cites W2076778816 @default.
• W2171665032 cites W2077492307 @default.
• W2171665032 cites W2078756278 @default.
• W2171665032 cites W2082785987 @default.
• W2171665032 cites W2090056732 @default.
• W2171665032 cites W2091246778 @default.
• W2171665032 cites W2092297520 @default.
• W2171665032 cites W2092630032 @default.
• W2171665032 cites W2095210290 @default.
• W2171665032 cites W2098681351 @default.
• W2171665032 cites W2104364004 @default.
• W2171665032 cites W2107361510 @default.
• W2171665032 cites W2116297500 @default.
• W2171665032 cites W2116394959 @default.
• W2171665032 cites W2121314041 @default.
• W2171665032 cites W2123515807 @default.
• W2171665032 cites W2127606003 @default.
• W2171665032 cites W2137959890 @default.
• W2171665032 cites W2138614007 @default.
• W2171665032 cites W2145044290 @default.
• W2171665032 cites W2146634225 @default.
• W2171665032 cites W2147631083 @default.
• W2171665032 cites W2148160168 @default.
• W2171665032 cites W2149651943 @default.
• W2171665032 cites W2151901827 @default.
• W2171665032 cites W2154819798 @default.
• W2171665032 cites W2155730420 @default.
• W2171665032 cites W2156387230 @default.
• W2171665032 cites W2158838439 @default.
• W2171665032 cites W2165896086 @default.
• W2171665032 cites W2170258599 @default.
• W2171665032 cites W2412542340 @default.
• W2171665032 cites W4247294857 @default.
• W2171665032 cites W4252785935 @default.
• W2171665032 doi "https://doi.org/10.1186/1471-2407-13-378" @default.
• W2171665032 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3848757" @default.
• W2171665032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23927827" @default.
• W2171665032 hasPublicationYear "2013" @default.
• W2171665032 type Work @default.
• W2171665032 sameAs 2171665032 @default.
• W2171665032 citedByCount "51" @default.
• W2171665032 countsByYear W21716650322014 @default.
• W2171665032 countsByYear W21716650322015 @default.
• W2171665032 countsByYear W21716650322016 @default.
• W2171665032 countsByYear W21716650322017 @default.
• W2171665032 countsByYear W21716650322018 @default.
• W2171665032 countsByYear W21716650322019 @default.
• W2171665032 countsByYear W21716650322020 @default.
• W2171665032 countsByYear W21716650322021 @default.
• W2171665032 countsByYear W21716650322022 @default.
• W2171665032 countsByYear W21716650322023 @default.
• W2171665032 crossrefType "journal-article" @default.
• W2171665032 hasAuthorship W2171665032A5005931876 @default.
• W2171665032 hasAuthorship W2171665032A5026699953 @default.
• W2171665032 hasAuthorship W2171665032A5027854700 @default.
• W2171665032 hasAuthorship W2171665032A5030295153 @default.
• W2171665032 hasAuthorship W2171665032A5040566066 @default.
• W2171665032 hasAuthorship W2171665032A5049914982 @default.
• W2171665032 hasAuthorship W2171665032A5072764332 @default.
• W2171665032 hasBestOaLocation W21716650321 @default.
• W2171665032 hasConcept C126322002 @default.
• W2171665032 hasConcept C142724271 @default.
• W2171665032 hasConcept C185592680 @default.
• W2171665032 hasConcept C202751555 @default.
• W2171665032 hasConcept C204232928 @default.
• W2171665032 hasConcept C2778608917 @default.

• next